Effects of Cardiopulmonary Bypass (CPB)-Leukocyte Filtration on Interleukins Serum Levels and Pulmonary Function (PulmFunction)
Primary Purpose
Systemic Inflammatory Response Syndrome (SIRS), Leukocyte Disorders, Complications Due to Coronary Artery Bypass Graft
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Filtering group LG-6, Pall Biomedical Products
Sponsored by
About this trial
This is an interventional prevention trial for Systemic Inflammatory Response Syndrome (SIRS) focused on measuring Coronary Artery Bypass Surgery, Cardiopulmonary Bypass, Leukocyte Reduction Filtrations, Pulmonary Function, Systemic Inflammatory Response
Eligibility Criteria
Inclusion Criteria:
- Patients undergoing coronary artery bypass grafting (CABG), having their physical state classified as PII and PIII, according to the American Society of Anesthesiologists (ASA). Surgical risk was stratified according to Parsonnet criteria, and only patients considered low to moderate risk were admitted.
Exclusion Criteria:
- Subjects older than 70 years
- Body mass index (BMI) over 35 kg/m2
- Congestive heart failure (CHF) greater than class III (NYHA)
- Left ventricle ejection fraction less than 40%
- Submitted to recent surgery
- creatinine ≥ 1.4 mg / dL or in use of oral anticoagulants were excluded
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
Control group
Filtering Group
Arm Description
In the Control group, a standard arterial line filter was inserted on CPB circuit.
In the Filtering group, a leukocyte filter was inserted in the arterial line circuit.
Outcomes
Primary Outcome Measures
Effects of CPB-leukocyte Filtration on Interleukins Serum Levels and Pulmonary Function.
The primary outcome was the evaluation of the effects of leukocyte filtration on lung function in patients undergoing coronary surgery.
Secondary Outcome Measures
Evaluation of the effects of leukocyte filtration on the inflammatory response in patients undergoing coronary surgery.
The secondary outcome was the evaluation of the effects of leukocyte filtration on the inflammatory response in patients undergoing coronary surgery.
Full Information
NCT ID
NCT01469676
First Posted
June 22, 2011
Last Updated
November 9, 2011
Sponsor
University of Sao Paulo
Collaborators
InCor Heart Institute, Fundação de Amparo à Pesquisa do Estado de São Paulo
1. Study Identification
Unique Protocol Identification Number
NCT01469676
Brief Title
Effects of Cardiopulmonary Bypass (CPB)-Leukocyte Filtration on Interleukins Serum Levels and Pulmonary Function
Acronym
PulmFunction
Official Title
Effects of CPB-leukocyte Filtration on Interleukins Serum Levels and Pulmonary Function.
Study Type
Interventional
2. Study Status
Record Verification Date
November 2011
Overall Recruitment Status
Completed
Study Start Date
February 2007 (undefined)
Primary Completion Date
February 2010 (Actual)
Study Completion Date
October 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Sao Paulo
Collaborators
InCor Heart Institute, Fundação de Amparo à Pesquisa do Estado de São Paulo
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To test the hypothesis that leukocyte filtering during cardiopulmonary bypass (CPB) might reduce the inflammatory response and protect the lungs against the acute injury
Detailed Description
BACKGROUND AND OBJECTIVES: The extension of the systemic inflammatory response observed after cardiopulmonary bypass (CPB) in cardiac surgery is associated to postoperative pulmonary dysfunction degree. The leukocyte depletion during CPB can modify that response. The aim of this study was to evaluate the effects of leukocyte filtering on the inflammatory response and lung function in patients undergoing coronary artery bypass grafting.
METHODS: After approval by the institutional ethical committee, a prospective randomized study was performed to compare nine patients undergoing coronary artery bypass grafting (CABG) using leukocyte filtration in the arterial line (LG-6, Pall Biomedical Products) and eleven others submitted to standard CPB. Chest CT, oxygenation analysis and a complete leucocyte count were performed before surgery. After intravenous anesthesia induction, patients were mechanically ventilated with tidal volume of 8 mL.kg-1, with FiO2 0.6, and PEEP of 5 cm H2O, except during CPB. Haemodynamic data, PaO2/FiO2, shunt fraction, interleukins, elastase and myeloperoxidase were evaluated before and after CPB, at the end of surgery, 6, 12 and 24 hours after surgery. Chest CT was repeated on the first postoperative day. Data were analyzed using two-factor ANOVA for repeated measures.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Systemic Inflammatory Response Syndrome (SIRS), Leukocyte Disorders, Complications Due to Coronary Artery Bypass Graft
Keywords
Coronary Artery Bypass Surgery, Cardiopulmonary Bypass, Leukocyte Reduction Filtrations, Pulmonary Function, Systemic Inflammatory Response
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Participant
Allocation
Randomized
Enrollment
22 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Control group
Arm Type
No Intervention
Arm Description
In the Control group, a standard arterial line filter was inserted on CPB circuit.
Arm Title
Filtering Group
Arm Type
Experimental
Arm Description
In the Filtering group, a leukocyte filter was inserted in the arterial line circuit.
Intervention Type
Device
Intervention Name(s)
Filtering group LG-6, Pall Biomedical Products
Other Intervention Name(s)
LeukoGard-6, Leukocyte depletion, Leukoreduction
Intervention Description
In Filtering group, a Leukocyte filter (LG-6, Pall Biomedical Products) was placed on the CPB arterial line circuit, trying to filter the white blood cells.
Primary Outcome Measure Information:
Title
Effects of CPB-leukocyte Filtration on Interleukins Serum Levels and Pulmonary Function.
Description
The primary outcome was the evaluation of the effects of leukocyte filtration on lung function in patients undergoing coronary surgery.
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Evaluation of the effects of leukocyte filtration on the inflammatory response in patients undergoing coronary surgery.
Description
The secondary outcome was the evaluation of the effects of leukocyte filtration on the inflammatory response in patients undergoing coronary surgery.
Time Frame
24 hours
10. Eligibility
Sex
All
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients undergoing coronary artery bypass grafting (CABG), having their physical state classified as PII and PIII, according to the American Society of Anesthesiologists (ASA). Surgical risk was stratified according to Parsonnet criteria, and only patients considered low to moderate risk were admitted.
Exclusion Criteria:
Subjects older than 70 years
Body mass index (BMI) over 35 kg/m2
Congestive heart failure (CHF) greater than class III (NYHA)
Left ventricle ejection fraction less than 40%
Submitted to recent surgery
creatinine ≥ 1.4 mg / dL or in use of oral anticoagulants were excluded
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maria José C Carmona, phd
Organizational Affiliation
U Sao Paulo
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Effects of Cardiopulmonary Bypass (CPB)-Leukocyte Filtration on Interleukins Serum Levels and Pulmonary Function
We'll reach out to this number within 24 hrs